Reversal of .beta./A4 amyloid peptide induced morphological changes in neuronal cells by antisense oligonucleotides
AssigneeThe General Hospital Corporation
InventorsCharles A. Marotta, Ronald E. Majocha, Sudhir Agrawal
Life of this patent
Estimating the term…
Abstract
The invention provides oligonucleotides that inhibit the expression of .beta./A4 peptide of Alzheimer's disease and Down's syndrome, and further provides methods for reversing morphological changes caused in neuronal cells by .beta./A4 peptide.
Claims10
An oligonucleotide that is capable of reversing morphological changes induced upon cells by beta/A4 peptide, the oligonucleotide having from about 8 to about 100 nucleotides and being complementary to a nucleotide sequence of an RNA encoding beta/A4 peptide, such sequence comprising the initiation codon for APP, wherein the oligonucleotide has at least one internucleotide linkage selected from the group consisting of phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate and sulfone internucleotide linkages.
An oligonucleotide that is capable of reversing morphological changes induced upon cells by beta/A4 peptide, the oligonucleotide having from about 8 to about 100 nucleotides and being complementary to a nucleotide sequence of an RNA encoding APP, wherein the oligonucleotide has at least one internucleotide linkage selected from the group consisting of phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate and sulfone internucleotide linkages.
Dependencies are inferred from the claim text.